CollPlant to buy Israel's LightSolver in all-equity deal, ceding 19.7% stake
What's the deal? CollPlant BiotechnologiesDealroom has a profile for this one. Try Dealroom → (Nasdaq: CLGN) signed a definitive agreement to acquire LightSolver, an Israeli deep-tech company developing photonic computing hardware. The all-equity transaction is expected to close this week.
The terms: Consideration is equity-centric, with no cash upfront. CollPlant will issue 3,734,476 new ordinary shares — 19.7% of its pre-deal share capital — plus pre-funded warrants for 6,134,363 shares.
An additional 224,078,345 milestone-based warrants and 2,261,966 rollover options are tied to LightSolver hitting specified technological and commercial targets. Issuance above an equity blocker requires shareholder approval.
What's LightSolver building? The company has developed the Laser Processing Unit (LPU), an all-optical computing platform that uses lasers rather than electronic transistors to perform calculations. It is designed to sit alongside CPUs and GPUs, targeting simulation, optimisation, and Physical AI workloads.
The quantum-inspired architecture runs at room temperature, avoiding the cryogenic conditions many quantum systems require. Commercial availability is targeted for 2028.
Why it matters: The deal moves CollPlant into high-performance and photonic computing, markets pitched as answers to the speed, energy, and heat limits of semiconductor-based computing. LightSolver has moved past research into validation with global organisations, including a funded engineering partnership with BoeingDealroom has a profile for this one. Try Dealroom → (NYSE: BA) on aerospace simulations.
Other collaborators span defence, oil and gas, energy, and engineering software firms, according to the company.
What could go wrong? The structure carries significant potential dilution. Beyond the 19.7% upfront stake, the pre-funded warrants, 224 million milestone warrants, and rollover options could sharply expand CollPlant's share count if issued or exercised.
Much of that consideration hinges on LightSolver meeting undefined milestones and on shareholders approving issuance above the equity blocker.
The signal: A biotechnology firm pivoting into photonic computing via an all-stock acquisition is unusual, and the milestone-heavy terms shift risk toward performance rather than upfront cash. It reflects rising commercial interest in alternatives to GPU clusters for the most demanding compute workloads.
Read more: stocktitan.net
Image credit: Generated with Gemini
